2019 American Transplant Congress
Impact of Liver Recipient Genotype on Tacrolimus
*Purpose: In kidney transplant recipients, recipient genotype (CYP3A5 *3) has the greatest influence on tacrolimus pharmacokinetics (PK). However, in liver transplant recipient, donor liver and…2019 American Transplant Congress
A Clinical Pharmacogenetic Model to Predict the Efficacy of Sirolimus during the Early Administration in Renal Transplant Recipients
No.300 Guangzhou Road of Nanjing, Nanjing, China
*Purpose: This study was to develop a clinical pharmacogenetic model to predict the efficacy of sirolimus during the early administration in renal transplant recipients. 70…2019 American Transplant Congress
Association of Tacrolimus-Level Variance with De Novo DSA within the First 2 Years after Renal Transplantation
*Purpose: Patients that receive an HLA-mismatched kidney transplant (KT) have an increased likelihood to develop de novo DSA (dnDSA). Ideally, immunosuppression is properly adjusted and…2019 American Transplant Congress
Intravenous Immunoglobulin Significantly Reduces Bioavailability of Concomitantly Administered Anti-C5 Monoclonal Antibodies
*Purpose: Awareness of drug-drug interactions is critical in management of organ transplant recipients. However, there is little understanding of the possibility of biologic agents interfering…2019 American Transplant Congress
Tacrolimus Concentration/Dose Ratio is an Independent Predictor of Death-Censored Kidney Allograft Survival
*Purpose: Tacrolimus (Tac) remains the cornerstone of kidney transplantation immunosuppression. Its narrow therapeutic index demands therapeutic drug monitoring. The C/D ratio (Tac trough concentration /…2019 American Transplant Congress
Comparison of Initial Sirolimus (SRL) and Everolimus (EVR) Exposure Patterns in Kidney Transplant Recipients
Hospital do Rim, Nephrology Division, EPM - UNIFESP, São Paulo, Brazil
*Purpose: Despite distinct pharmacokinetic properties, SRL and EVR bind to the same intracellular target protein, suggesting that equivalent blood concentrations may exert similar pharmacodynamic effect.*Methods:…2019 American Transplant Congress
Mycophenolic Acid Area under the Curve Monitoring via Limited Sampling Strategy in Pediatric Heart Transplant Recipients
*Purpose: The study aim was to investigate exposure to mycophenolic acid (MPA), the active metabolite of mycophenolate mofetil (MMF), after pediatric orthotopic heart transplantation (pOHT).…2019 American Transplant Congress
Pharmacokinetics of Innovative versus Generic Valganciclovir in Kidney Transplant Recipients
*Purpose: In kidney transplant recipients (KTR), cytomegalovirus (CMV) is a common viral infection associated with significant morbidity and mortality. In the absence of prophylaxis, CMV…2019 American Transplant Congress
Drug Metabolizing Capacity Of The Liver In Liver Donors Recovers Fully By One Month Post Donation
*Purpose: In liver donors, hepatic volume recovers to pre donation values in 2-6 months after surgery. However, there is limited information on the recovery of…2019 American Transplant Congress
Efficacy And Safety Of Febuxostat In Renal Transplant Recipients With Hyperuricemia
*Purpose: To assess the efficacy and safety of febuxostat in the treatment of hyperuricemia in renal transplant recipients.*Methods: A total number of 124 renal transplant…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 12
- Next Page »